The cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells

Cells Tissues Organs

Volumn 193, Issue 1-2, 2010, Pages 98-113

  Allington, Tressa M ^a   Schiemann, William P ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Breast cancer; C Abl; Epithelial mesenchymal transition; Metastasis; Signal transduction; Transforming growth factor

Indexed keywords

ABELSON KINASE; CAPECITABINE; EPHRIN B2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; RECOMBINANT SOMATOMEDIN C; SCATTER FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; DNA DAMAGE; DRUG EFFICACY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; LUNG CANCER; MAMMAL CELL; METASTASIS; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CANCER; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANIMALS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

EID: 78650517027     PISSN: 14226405     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320163     Document Type: Article

References (102)

1. Agami, R., G. Blandino, M. Oren, Y. Shaul (1999) Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399:809-813.
2. Allington, T. M., A. J. Galliher-Beckley, W. P. Schiemann (2009) Activated Abl kinase inhibits oncogenic TGF-β signaling and tumorigenesis in mammary tumors. FASEB J 23:4231-4243.
3. Bakin, A. V., A. K. Tomlinson, N. A. Bhowmick, H. L. Moses, C. L. Arteaga (2000) Phosphatidylinositol 3-kinase function is required for TGF-β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275:36803-36810.
4. Barcellos-Hoff, M. H., R. J. Akhurst (2009) TGF-β in breast cancer: too much, too late. Breast Cancer Res 11:202.
5. Baskaran, R., L. D. Wood, L. L. Whitaker, C. E. Canman, S. E. Morgan, Y. Xu, C. Barlow, D. Baltimore, A. Wynshaw-Boris, M. B. Kastan, JY. Wang (1997) Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387:516-519.
6. Benson, J. R. (2004) Role of TGF-β in breast carcinogenesis. Lancet Oncol 5:229-239.
7. Bhowmick, N. A., A. Chytil, D. Plieth, A. E. Gorska, N. Dumont, S. Shappell, M. K. Washington, E. G. Neilson, H. L. Moses (2004a) TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848-851.
8. Bhowmick, N. A., E. G. Neilson, H. L. Moses (2004b) Stromal fibroblasts in cancer initiation and progression. Nature 432:332-337.
9. 1 signaling is necessary for TGF-β activation of p38MAPK and epithelial plasticity. J Biol Chem 276:46707-46713.
10. Bierie, B., H. L. Moses (2006) Tumour microenvironment: TGF-β: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506-520.
11. Buck, M. B., C. Knabbe (2006) TGF-β signaling in breast cancer. Ann NY Acad Sci 1089:119-126.
12. Butcher, D. T., T. Alliston, V. M. Weaver (2009) A tense situation: forcing tumour progression. Nat Rev Cancer 9:108-122.
13. Chau, B. N., T. T. Chen, Y. Y. Wan, J. DeGregori, JY. Wang (2004) Tumor necrosis factor-α-induced apoptosis requires p73 and c-ABL activation downstream of RB degradation. Mol Cell Biol 24:4438-4447.
14. Chen, J., C. Rocken, B. Nitsche, C. Hosius, H. Gschaidmeier, S. Kahl, P. Malfertheiner, M. P. Ebert (2006) The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett 233:328-337.
15. Cheng, N., N. A. Bhowmick, A. Chytil, A. E. Gorksa, K. A. Brown, R. Muraoka, CL. Arteaga, E. G. Neilson, S. W. Hayward, H. L. Moses (2005) Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP-and HGF-mediated signaling networks. Oncogene 24:5053-5068.
16. Chew, H. K., W. E. Barlow, K. Albain, D. Lew, A. Gown, D. F. Hayes, J. Gralow, G. N. Hortobagyi, R. Livingston (2008) A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. Clin Breast Cancer 8:511-515.
17. Cristofanilli, M., P. Morandi, S. Krishnamurthy, J. M. Reuben, B. N. Lee, D. Francis, D. J. Booser, M. C Green, B. K. Arun, L. Pusztai, A. Lopez, R. Islam, V. Valero, G. N. Hortobagyi (2008) Imatinib mesylate (Gleevec) in advanced breast cancer-expressing c-Kit or PDGFR-β: clinical activity and biological correlations. Ann Oncol 19:1713-1719.
18. Daniels, C. E., M. C. Wilkes, M. Edens, T. J. Kottom, S. J. Murphy, A. H. Limper, E. B. Leof (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308-1316.
19. Druker, B. J. (2006) Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 354:2594-2596.
20. Echarri, A., A. M. Pendergast (2001) Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway. Curr Biol 11:1759-1765.
21. Erler, J. T., V. M. Weaver (2009) Three-dimensional context regulation of metastasis. Clin Exp Metastasis 26:35-49.
22. Frasca, F., P. Vigneri, V. Vella, R. Vigneri, JY. Wang (2001) Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor. Oncogene 20:3845-3856.
23. 3 integrin and Src facilitate TGF-β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 8: R42.
24. Galliher, A. J., W. P. Schiemann (2007) Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 67:3752-3758.
25. Galliher-Beckley, A. J., W. P. Schiemann (2008) Grb2 binding to Tyr284 in TβR-II is essential for mammary tumor growth and metastasis stimulated by TGF-β. Carcinogenesis 29:244-251.
26. Gharibo, M., L. Patrick-Miller, L. Zheng, L. Guensch, P. Juvidian, E. Poplin (2008) A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer. Pancreas 36:341-345.
27. Hamer, G., I. S. Gademan, H. B. Kal, D. G. de Rooij (2001) Role for c-Abl and p73 in the radiation response of male germ cells. Oncogene 20:4298-4304.
28. Hanahan, D., R. A. Weinberg (2000) The hallmarks of cancer. Cell 100:57-70.
29. Heldin, C. H., M. Landstrom, A. Moustakas (2009) Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelialmesenchymal transition. Curr Opin Cell Biol 21:166-176.
30. Huber, M. A., N. Azoitei, B. Baumann, S. Grunert, A. Sommer, H. Pehamberger, N. Kraut, H. Beug, T. Wirth (2004) NF-kB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114:569-581.
31. Hugo, H, M. L. Ackland, T. Blick, M. G Lawrence, J. A. Clements, E. D. Williams, EW. Thompson (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213:374-383.
32. Hunter, T. (2007) Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest 117:2036-2043.
33. Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu, M. J. Thun (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
34. Kain, K. H., S. Gooch, R. L. Klemke (2003) Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion. Oncogene 22:6071-6080.
35. Kain, K. H., R. L. Klemke (2001) Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes. J Biol Chem 276:16185-16192.
36. Kalluri, R., R. A. Weinberg (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428.
37. Lamouille, S., R. Derynck (2007) Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178:437-451.
38. Lamouille, S., R. Derynck (2011) Emergence of the phosphoinositide 3-kinase-akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition. Cells Tissues Organs 193:8-22.
39. Lee, Y. H., A. R. Albig, M. Regner, B. J. Schiemann, W. P. Schiemann (2008) Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-β in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis 29:2243-2251.
40. Lewis, J. M., R. Baskaran, S. Taagepera, M. A. Schwartz, JY. Wang (1996) Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci USA 93:15174-15179.
41. Li, L. S., J. C Morales, A. Hwang, M. W. Wagner, D. A. Boothman (2008) DNA mismatch repair-dependent activation of c-Abl/p73α/GADD45alpha- mediated apoptosis. J Biol Chem 283:21394-21403.
42. Lin, A. M., B. I. Rini, M. K. Derynck, V. Weinberg, M. Park, C. J. Ryan, J. E. Rosenberg, G. Bubley, E. J. Small (2007a) A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 5:323-328.
43. Lin, A. M., B. I. Rini, V. Weinberg, K. Fong, C. J. Ryan, J. E. Rosenberg, L. Fong, E. J. Small (2006) A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98:763-769.
44. Lin, J., R. Arlinghaus (2008) Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene 27:4385-4391.
45. Lin, J., T. Sun, L. Ji, W. Deng, J. Roth, J. Minna, R. Arlinghaus (2007b) Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26:6989-6996.
46. Mani, S. A., W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan, AY. Zhou, M. Brooks, F. Reinhard, C. C. Zhang, M. Shipitsin, L. L. Campbell, K. Polyak, C. Brisken, J. Yang, R. A. Weinberg (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715.
47. Massague, J. (2008) TGF-β in Cancer. Cell 134:215-230.
48. Masszi, A., A. Kapus (2011) Smaddening complexity: The role of Smad3 in epithelial-myofibroblast transition. Cells Tissues Organs 193:41-52.
49. Mauro, M. J., B. J. Druker (2001) STI571: targeting BCR-ABL as therapy for CML. Oncologist 6:233-238.
50. Mauro, M. J., M. O'Dwyer, M. C. Heinrich, B. J. Druker (2002) STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20:325-334.
51. Miller, C. T., G. Chen, T. G. Gharib, H. Wang, D. G Thomas, D. E. Misek, T. J. Giordano, J. Yee, M. B. Orringer, S. M. Hanash, D. G. Beer (2003) Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 22:7950-7957.
52. Modi, S., A. D. Seidman, M. Dickler, M. Moasser, G. D'Andrea, M. E. Moynahan, J. Menell, K. S. Panageas, L. K. Tan, L. Norton, C. A. Hudis (2005) A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 90:157-163.
53. Neil, J. R., K. M. Johnson, R. A. Nemenoff, W. P. Schiemann (2008) Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-β through a PGE2-dependent mechanisms. Carcinogenesis 29:2227-2235.
54. Neil, J. R., W. P. Schiemann (2008) Altered TAB1: IkB kinase interaction promotes TGF-β-mediated NF-kB activation during breast cancer progression. Cancer Res 68:1462-1470.
55. Neil, J. R., M. Tian, W. P. Schiemann (2009) X-linked inhibitor of apoptosis protein and its E3 ligase activity promote TGF-β-mediated NF-kB activation during breast cancer progression. J Biol Chem 284:21209-21217.
56. Noren, N. K., G. Foos, C. A. Hauser, E. B. Pasquale (2006) The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol 8:815-825.
57. 1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10:2462-2477
58. Ozdamar, B., R. Bose, M. Barrios-Rodiles, H. R. Wang, Y. Zhang, J. L. Wrana (2005) Regulation of the polarity protein Par6 by TGF-β receptors controls epithelial cell plasticity. Science 307:1603-1609.
59. Pardali, K., A. Moustakas (2007) Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775:21-62.
60. Pendergast, A. M. (1996) Nuclear tyrosine kinases: from Abl to WEE1. Curr Opin Cell Biol 8:174-181.
61. Pendergast, A. M. (2002) The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85:51-100.
62. Perou, C.M., T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale, P. O. Brown, D. Botstein (2000) Molecular portraits of human breast tumours. Nature 406:747-752.
63. Plattner, R., L. Kadlec, K. A. DeMali, A. Kazlauskas, A. M. Pendergast (1999) c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 13:2400-2411.
64. Polyak, K., R. A. Weinberg (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265-273.
65. Schiemann, W. P. (2007) Targeted TGF-β chemotherapies: friend or foe in treating human malignancies? Expert Rev Anticancer Ther 7:609-611.
66. Shaul, Y. (2000) c-Abl: activation and nuclear targets. Cell Death Differ 7:10-16.
67. Shipitsin, M., L. L. Campbell, P. Argani, S. Weremowicz, N. Bloushtain-Qimron, J. Yao, T Nikolskaya, T. Serebryiskaya, R. Beroukhim, M. Hu, M. K. Halushka, S. Sukumar, L. M. Parker, K. S. Anderson, L. N. Harris, J. E. Garber, A. L. Richardson, S. J. Schnitt, Y. Nikolsky, R. S. Gelman, K. Polyak (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259-273.
68. Sirvent, A., A. Boureux, V. Simon, C. Leroy, S. Roche (2007) The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene 26:7313-7323.
69. Sokol, J. P., J. R. Neil, B. J. Schiemann, W. P. Schiemann (2005) The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by TGF-β. Breast Cancer Res 7: R844-R853.
70. Sorlie, T., CM. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. Eystein Lonning, A. L. Borresen-Dale (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
71. Sorlie, T., R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, CM. Perou, P. E. Lonning, P. O. Brown, A. L. Borresen-Dale, D. Botstein (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423.
72. Soverini, S., G. Martinelli, I. Iacobucci, M. Baccarani (2008) Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther 8:853-864.
73. Srinivasan, D., R. Plattner (2006) Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 66:5648-5655.
74. Srinivasan, D., J. T. Sims, R. Plattner (2008) Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 27:1095-1105.
75. Suzuki, J., T. Shishido (2007) Regulation of cellular transformation by oncogenic and normal Abl kinases. J Biochem 141:453-458.
76. Taagepera, S., D. McDonald, J. E. Loeb, L. L. Whitaker, A. K. McElroy, J. Y. Wang, T. J. Hope (1998) Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci USA 95:7457-7462.
77. Tang, B., N. Yoo, M. Vu, M. Mamura, J. S. Nam, A. Ooshima, Z. Du, P. Y. Desprez, M. R. Anver, A. M. Michalowska, J. Shih, W. T. Parks, L. M. Wakefield (2007) TGF-β can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res 67:8643-8652.
78. Thiery, J. P. (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740-746.
79. Tian, M., W. P. Schiemann (2009a) PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-β signaling during mammary tumorigenesis. FASEB J 24:1105-1116.
80. Tian, M., W. P. Schiemann (2009b) The TGF-β paradox in human cancer: an update. Future Oncol 5:259-271.
81. Truong, T., G. Sun, M. Doorly, J. Y. Wang, M. A. Schwartz (2003) Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci USA 100:10281-10286.
82. Valcourt, U, M. Kowanetz, H. Niimi, C. H. Heldin, A. Moustakas (2005) TGF-β and the Smad signaling pathway support transcriptomic reprogramming during epithelialmesenchymal cell transition. Mol Biol Cell 16:1987-2002.
83. Vigneri, P., J. Y. Wang (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 7:228-234.
84. Wagner, M. W., L. S. Li, J. C. Morales, C. L. Galindo, H. R. Garner, W. G Bornmann, D. A. Boothman (2008) Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses. J Biol Chem 283:21382-21393.
85. Wang, J. Y. (2006) Eph tumour suppression: the dark side of Gleevec. Nat Cell Biol 8:785-786.
86. Wang, J. Y., F. Ledley, S. Goff, R. Lee, Y. Groner, D. Baltimore (1984) The mouse c-Abl locus: molecular cloning and characterization. Cell 36:349-356.
87. Wang, S., M. C. Wilkes, E. B. Leof, R. Hirschberg (2005) Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19:1-11.
88. Wen, S. T., P. K. Jackson, R. A. Van Etten (1996) The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J 15:1583-1595.
89. Wendt, M. K., T. M. Allington, W. P. Schiemann (2009a) Mechanisms of the epithelial-mesenchymal transition by TGF-β. Future Oncol 5:1145-1168.
90. Wendt, M. K., W. P. Schiemann (2009) Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis. Breast Cancer Res 11: R68.
91. Wendt, M. K., J. A. Smith, W. P. Schiemann (2009b) p130Cas is required for mammary tumor growth and TGF-β-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem 284:34145-34156.
92. Wilkes, M. C., E. B. Leof (2006) TGF-β activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem 281:27846-27854.
93. Woodring, P. J., T. Hunter, J. Y. Wang (2001) Inhibition of c-Abl tyrosine kinase activity by filamentous actin. J Biol Chem 276:27104-27110.
94. Woodring, P. J., E. D. Litwack, D. D. O'Leary, GR. Lucero, J. Y. Wang, T. Hunter (2002) Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol 156:879-892.
95. Woodring, P. J., J. Meisenhelder, S. A. Johnson, G. L. Zhou, J. Field, K. Shah, F. Bladt, T. Pawson, M. Niki, P. P. Pandolfi, J. Y. Wang, T. Hunter (2004) c-Abl phosphorylates Dok1 to promote filopodia during cell spreading. J Cell Biol 165:493-503.
96. 1-induced EMT in vitro. Neoplasia 6:603-610.
97. Xu, J., S. Lamouille, R. Derynck (2009) TGF-β-induced epithelial to mesenchymal transition. Cell Res 19:156-172.
98. Yang, L., J. Huang, X. Ren, A. E. Gorska, A. Chytil, M. Aakre, D. P. Carbone, L. M. Matrisian, A. Richmond, PC. Lin, H. L. Moses (2008) Abrogation of TGF-β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23-35.
99. Yuan, Z. M., H. Shioya, T. Ishiko, X. Sun, J. Gu, Y. Y. Huang, H. Lu, S. Kharbanda, R. Weichselbaum, D. Kufe (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399:814-817.
100. Zandy, N. L., A. M. Pendergast (2008) Abl tyrosine kinases modulate cadherin-dependent adhesion upstream and downstream of Rho family GTPases. Cell Cycle 7:444-448.
101. Zandy, N. L., M. Playford, A. M. Pendergast (2007) Abl tyrosine kinases regulate cell-cell adhesion through Rho GTPases. Proc Natl Acad Sci USA 104:17686-17691.
102. Zhu, J., J. Y. Wang (2004) Death by Abl: a matter of location. Curr Top Dev Biol 59:165-192.